C. diff Risk


Oral Bioavailability


Approximate Cost



Endocarditis/bloodstream/joint infection
6-10mg/kg IV daily

Skin and soft tissue infections
4mg/kg IV daily

Unknown for severe hepatic dysfunction

General Information

Common Usage

Targeted therapy of resistant gram positive infections when use of first line agents precluded by allergy or intolerance

Drug Monitoring

Creatine kinase and creatinine at least weekly
(more frequently if renal function changing or unstable)

Adverse Effects

  • GI side effects common

  • Rash

  • Phlebitis

  • Increased INR

  • Myopathy including rhabdomyolysis

Major Interactions

Statins and fibrates - Increased myopathy. Monitor creatine kinase or hold while on daptomycin therapy.

Additional Information

IV Administration

  • Dilute in 100 mL NS and administer over 30 min.

  • Concentration range: 2.5-20 mg/mL

EH Prescribing Restrictions

  • Pharmacist review (with ID consult if required)

  • See Systemic Antimicrobial Formulary Policy (PHA-305) for full details

Community IV Formulary (Metro Area)

Inactivated by pulmonary surfactant : Not indicated for pulmonary infection.


Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

CSF penetration: Poor

Lung penetration: Poor

Urine penetration: Therapeutic